{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 44 of 122', 'in a sudden increase in blood pressure. An assessment of the benefits and risks of using a', 'medication with known cardiovascular side effects at the same time as AR101 should be', 'discussed with a medical monitor before its use.', 'Antihistamines and other medications that could interfere with the assessment of an allergic', 'reaction must be discontinued for 5 half-lives of the medication before the SPT, first dose of', 'AR101, and food challenges. The prescribing information must be reviewed to determine the', \"half-life of each medication for the subject's relevant age group.\", 'Symptomatic treatment should be used to supplement dose reduction and not as a substitute', 'for it. Medications for the prophylaxis of symptoms of chronic or recurrent adverse events', '(eg, H1 or H2 histamine blockers, proton pump inhibitors, inhaled beta-adrenergic agonists)', 'should not be started in advance of symptoms; exceptions may be allowed on a case-by-case', 'basis following approval by the medical monitor. The use of such medications should be', 'minimized, and then discontinued at the earliest opportunity as medically appropriate.', 'Systemic steroid use is limited to 3 weeks. Up-dosing must not occur until 3 days after', 'oral corticosteroids are discontinued. Topical steroid use is allowed after an SPT.', '7.3', 'Rescue Medications', 'All rescue medications (ie, any medication used to treat symptoms of an acute allergic', 'reaction) must be recorded on the case report form. The adverse event requiring the use of', 'rescue medications must be recorded on the adverse event case report form and in the', \"subject's source documents.\", 'Medications for the treatment of individual acute allergic reactions (eg, antihistamine,', 'epinephrine, IV fluids, beta-adrenergic agonist [eg, albuterol by inhaler or nebulizer],', 'oxygen, glucocorticosteroids) are to be used as indicated.', 'An epinephrine auto-injector device will be provided or prescribed as appropriate to subjects', 'and parents/caregivers who do not have one. The expiration date and record of training on', \"the epinephrine auto-injector device must be documented in the subject's source documents.\", '7.4', 'Prohibited Medications', 'Prohibited medications are presented in Table 7.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 45 of 122', 'Table 7:', 'Prohibited Medications', 'Medication or Treatment', 'Comment on Use', 'Angiotensin II receptor blockers', 'Angiotensin-converting enzyme inhibitors', 'Beta-blockers (oral)', 'Calcium channel blockers', 'Immunomodulatory medications,', 'Examples include cyclosporine, tacrolimus, antitumor necrosis', 'including immunosuppressive medications', 'alpha drugs, anti-IgE drugs, anti-IL-5 or IL-5 receptor-targeted', 'drugs.', 'Before administering a potentially immunomodulatory drug', 'during the study, discuss its use with a medical monitor.', 'Systemic corticosteroids (oral,', 'Used > 3 consecutive weeks during the study. If used,', 'intramuscular, intravenous)', 'up-dosing is not allowed during the 3 days after cessation of', 'oral corticosteroids.', 'Therapeutic immunomodulatory antibodies', 'May not be used within 6 months before screening or initiated', '(experimental or commercially available)', 'during the study.', 'Tricyclic antidepressants', 'Ig, immunoglobulin; IL, interleukin.', '8 SAFETY CONSIDERATIONS', 'This section defines the procedures for safety monitoring; requirements and guidelines for', 'identifying, grading, and reporting adverse events; and special safety considerations', '(assessment of allergy symptoms, treatment, dose adjustment, adverse events of interest, and', 'other notable events).', 'Study assessments of safety include adverse events, physical examinations, vital signs, peak', 'expiratory flow rate (PEFR), and evaluation of asthma.', '8.1', 'Safety Monitoring', 'The sponsor will periodically monitor safety data during the study in addition to reviewing', 'individual safety case reports, by examining the incidence and severity of adverse events and', 'serious adverse events and other data (eg, aggregate analysis of data from other AR101', 'studies). Any relevant safety concerns will be communicated to the investigators, ethics', 'committees (ECs; a global term including institutional review boards, independent ethics', 'committees, research ethics committees, and the like), and regulatory authorities, as', 'appropriate.', '8.2', 'Adverse Event Definitions', 'This section provides definitions for adverse events, adverse reactions, serious adverse', 'events, unexpected adverse events, suspected unexpected serious adverse reactions', '(SUSARs), and adverse events of interest for all subjects.']\n\n###\n\n", "completion": "END"}